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Background: S-phase kinase-associated protein 2 (Skp2) is a member of mammalian F-box proteins. The purpose of
this study is to clarify the prognostic significance of expression of Skp2 related to gender, estrogen receptor (ER) and
progesterone receptor (PGR) in soft tissue sarcomas (STS). Skp2 has been demonstrated to display an oncogenic
function since its overexpression has been observed in many human cancers. Optimized treatment of STS requires
better identification of high-risk patients who will benefit from adjuvant therapy. The prognostic significance of Skp2
related to ER and PGR in STS has not been sufficiently investigated.
Methods: Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative
neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Skp2, ER and PGR.
Results: In univariate analyses, high tumor expression of Skp2 correlated (p = 0.050) with reduced disease-specific
survival (DSS). In subgroup analyses expression of PGR in males (p = 0.010) and in patients older than 60 years
(p = 0.043) were negative prognostic factors for DSS. Expression of ER in females was a positive prognostic factor
for DSS (p = 0.041). In co-expression analyses in the whole cohort, low expression of Skp2 in combination with low
expression of ER was positive for DSS (p = 0.049). In females high expression of Skp2 in combination with low
expression of ER was a negative prognosticator (p = 0.021). In the multivariate analyses, age (p = 0.012),
malignancy grade (p < 0.001), wide resection margins (P = 0.010), ER negative / PGR positive co-expression profile
(p = 0.002) and ER positive / PGR negative co-expression profile (p = 0.015) were independent negative prognostic
factors for DSS. In females expression of Skp2 (p = 0.006) was associated with shorter DSS.
Conclusions: We found diverse prognostic impacts of expression of Skp2, ER, PGR and DSS in male and female
patients with STS. In men, but not women, ER positive / PGR negative co-expression profile was an independent
negative prognostic factor for DSS. In women, but not men, high expression of Skp2 was associated with reduced DSS.Background
S-phase kinase-associated protein 2 (Skp2), a mammalian
F-box protein, displays S-phase-promoting function,
through ubiquitin-mediated proteolysis of the CDK inhibi-
tor p27. Skp2 has been shown to regulate cellular prolifera-
tion by targeting several cell cycle-regulated proteins for
ubiquitination and degradation. Skp2 has also been dem-
onstrated to display an oncogenic function since its
overexpression has been observed in many human cancers
[1]. High expression of Skp2 was reported to correlate with* Correspondence: sveinung.sorbye@unn.no
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reproduction in any medium, provided the orreduced overall survival in patients with myxofibrosarcoma
[2,3]. Di Vizio et al. [4] found that Skp2 expression corre-
lates with poor prognosis in gastrointestinal stromal tu-
mors (GIST). Oliveira found that Skp2 expression is
associated with cell proliferation and a worse prognosis in
182 soft tissue sarcomas [5]. In a previous study we showed
that high expression of Skp2 was a negative prognostic fac-
tor for DSS [6]. Interestingly, this correlation was statisti-
cally significant in females only, not in males. This may be
related to differences in expression of sexual hormone re-
ceptors (ER and PGR) in male and female STS patients
[7,8]. In previous studies, we have shown the prognostic
value of female steroid hormone receptors in STSs, both
alone and in coexpression with TGF-β, fascin and Akt
isoforms [7-9]. Such prognostic impact is not surprising,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation upon ligand-dependent and ligand-independent acti-
vation and are in essence growth factors. However, the
prognostic significance of Skp2 related to ER and PGR in
STS has not been sufficiently investigated.
The purpose of this study is to clarify the prognostic sig-
nificance of expression of Skp2 related to age, gender and
female steroid hormone receptors (ER and PGR) in non-
gastrointestinal stromal tumor (non-GIST) STS. To achieve
this, we analyzed the expression of these markers in 193Figure 1 Pictures of cores. Immunohistochemistry microscopic pictures o
expression of Skp2 and ER. (A) Skp2 low score; (B) Skp2 high score; (C) ER l
Original magnification ×100 and ×400.patients with non-GIST STS in relation to demographic
and other clinicopathological variables. Our major hypoth-
esis is that a different prognostic significance of Skp2 in
men and women exists and is related to diverse gender ex-
pressions of ER and PGR.
Methods
Primary tumor tissues from patients diagnosed with STS
at the University Hospital of North Norway (UNN) from
1973 to 2006 and the Hospitals of Arkhangelsk region,f tissue micro array of soft tissue sarcoma representing different
ow score; (D) ER high score; (E) PGR low score; (F) PGR high score;
Table 1 Prognostic clinicopathological variables as
predictors for disease-specific survival of soft tissue












<20 years 17 9 190 47 0.064
20–59 years 85 44 235 63
≥60 years 91 47 111 51
Gender
Male 81 42 235 60 0.087
Female 112 58 180 53
Nationality
Norwegian 131 68 228 62 0.005
Russian 62 32 81 44
Histology
Pleomorphic sarcoma 57 30 52 45 0.031
Leiomyosarcoma 47 24 89 64
Liposarcoma 32 17 NR 71
MF/MFT 16 8 123 56
Angiosarcoma 8 4 10 38
Rhabdomyosarcoma 9 5 NR 67
MPNST 9 5 NR 56
Synovial sarcoma 12 6 31 30
Other STS 3 2 NR -
Tumor localization
Extremities 78 40 201 56 0.922
Trunk 37 19 214 53
Retroperitoneum 27 14 135 51
Head/Neck 13 7 191 58
Visceral 38 20 202 62
Tumor size
<5 cm 57 30 257 69 0.026
5–9 cm 73 38 183 54




1 54 28 NR 81 <0.001
2 76 39 80 55
3 63 33 28 36
Surgical margins
Wide 97 50 254 66 <0.001
Non-wide 96 50 128 46
Table 1 Prognostic clinicopathological variables as
predictors for disease-specific survival of soft tissue
sarcomas (univariate analysis, log rank test), N = 193
(Continued)
Chemotherapy
No 156 81 207 57 0.669
Yes 37 19 180 51
Radiotherapy
No 132 68 216 58 0.190
Yes 61 32 152 52
Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST,
malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not
reached; NOS, non specified.
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496 potentially suitable patient records were identified
from the hospitals’ databases. Of these, 247 patients
were excluded due to missing clinical data (n = 86) or in-
adequate material for histological examination (n = 161).
In addition, 33 were excluded because of metastasis at
the time of the diagnosis, 13 were excluded because they
had no surgery, and 10 patients had both metastasis and
no surgery, leaving a total of 193 patients eligible for this
study. This report includes data for 131 Norwegian pa-
tients and 62 Russian patients followed until September
2009. The median follow-up was 38 (range 0–392)
months. Complete demographic and clinical data were
collected retrospectively. Formalin-fixed and paraffin-
embedded tumor specimens were obtained from the ar-
chives of the Departments of Pathology at UNN and
Arkhangelsk. The tumors were graded according to the
French Fédération Nationales des Centres de Lutte
Contre le Cancer (FNCLCC) system [WHO Tumors of
Soft Tissue and bone, 2002]. Wide resection margins
were defined as wide local resection with free micro-
scopic margins or amputation of the affected limb or
organ. Non-wide resection margins were defined as ei-
ther marginal or intralesional resection margins.
Microarray construction
Two pathologists (AV and SWS) reviewed the histology of
all soft tissue sarcoma cases. Tissue microarrays (TMAs)
were constructed for high-throughput molecular path-
ology research [10]. The most representative areas of
viable tumor cells were carefully selected and marked on
the hematoxylin and eosin (HE) slides for the correspond-
ing donor blocks and sampled for the tissue microarray
collector blocks. The TMAs were assembled using a
tissue-arraying instrument (Beecher Instruments).
Studies suggest that punching multiple 0.6 mm cores
from different regions captures the heterogeneity of the
tumors more accurately than a single 2 to 4 mm core
[11]. We therefore chose to use two 0.6-mm cores of
Table 2 Percentage of high expression of ER, PGR and
Skp2 in the different histological subtypes N = 193
Histology N ER (%)* PGR (%)** Skp2 (%)***
Pleomorphic sarcoma 57 40 26 37
Leiomyosarcoma 47 50 43 40
Liposarcoma 32 35 23 21
MF/MFT 16 27 29 36
Angiosarcoma 8 25 13 29
Rhabdomyosarcoma 9 50 56 67
MPNST 9 11 11 44
Synovial sarcoma 12 40 27 50
Other STS 3 67 33 67
Total 193 39 30 38
* Chi 8.516, p = 0.385.
** Chi 10.238, p = 0.249.
*** Chi 8.596, p = 0.377.
Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST,
malignant peripheral nerve sheath tumor.
Chi-square test showed no differences in percentage of high expression of ER,
PGR and Skp2 in the different histological subtypes.
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sections of the tumor and taking heterogeneity into
consideration, the two cores were selected to be as rep-
resentative as possible (different areas). To include all
core samples, 12 tissue array blocks were constructed.
Multiple 4-μm sections were cut with a Micron micro-
tome (HM355S) and stained with specific antibodies for
immunohistochemistry (IHC).
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house valid-
ation by the manufacturer of IHC analysis on paraffin-
embedded material. All staining was performed in the
Ventana Benchmark XT automated slide stainer (Ventana
Medical System, Illkirch, France). Before staining, the sec-
tions were incubated over night at 60 degrees Celsius.
Tissue sections were incubated with primary mouse mono-
clonal antibodies recognizing Skp2 (Zymed, catalog number
18–0307, 1:10), ER (Ventana, catalog number 790–4324,
ready to use) and PGR (Ventana, catalog number 790–
4296). The incubation periods were 40 minutes for Skp2,
32 minutes for ER and 24 min for PGR. This was followed
by application of liquid diaminobenzidine as substrate-
chromogen, yielding a brown reaction product at the site of
the target antigen (Ventana iView DAB Detection Kit, cata-
log number 760–091). iVIEW DAB Detection Kit is an in-
direct biotin streptavidin system for detecting mouse and
rabbit primary antibodies. The DAB chromogen produces a
dark brown precipitate that is readily visualized by light mi-
croscopy. All reagents are provided pre-diluted by the
manufacturer for use in Ventana Benchmark XT. Finally,
slides were counterstained with hematoxylin to visualizethe nuclei. For each antibody, including negative controls,
all TMA staining were performed in a single experiment.
In the TMA we also used cores from carcinomas and nor-
mal tissue as positive and negative controls.
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the slides for antibody staining of the
TMAs. The specimens were scanned at a low resolution
(1.25×) and a high resolution (20×) using an Olympus
BX 61 microscope with an automated platform (Prior).
The slides were loaded in the automated slide loader
(Applied Imaging SL 50). Representative and viable tis-
sue sections were scored manually on a computer screen
semi-quantitatively for nuclear and/or cytoplasmic
staining. The expression of Skp2, ER and PGR was
scored as: 0, negative; 1, weak; 2, intermediate and 3,
strong (Figure 1). The score for each patient was based
on the mean scoring of cores from one or several biop-
sies. To achieve maximal reproducibility in all cases,
every staining was dichotomized (negative and positive
expression). Positive expression was defined as mean
score > 0. All samples were anonymized and independ-
ently scored by two pathologists (AV and SWS). In case
of disagreement, the slides were re-examined and the
observers reached a consensus. When assessing a vari-
able for a given score, the scores of the other variables
and the outcome were hidden from the observers.
Statistical methods
All statistical analysis was performed using the statistical
package SPSS (Chicago, IL), version 18. The IHC scores
from each observer were compared for inter-observer reli-
ability by use of a two-way random effects model with
absolute agreement definition. The intra-class correlation
coefficient (reliability coefficient) was obtained from
these results.
Chi-square and Fisher exact tests were used to examine
the association between molecular marker expression and
various clinicopathological parameters. Univariate analyses
were done using the Kaplan-Meier method, and statistical
significance between survival curves was assessed by the
log rank test. Disease-specific survival (DSS) was deter-
mined from the date of histologically confirmed STS diag-
nosis. Correlation of marker expression was done using the
Pearson correlation (2-tailed) at the 0.05 and 0.01 levels.
Multivariate analysis was carried out using the Cox
proportional hazards model to assess the specific impact
of each pre-treatment variable on survival in the pres-
ence of other variables. Variables of significant value
from the univariate analysis were entered into the Cox
regression analysis. Probability for stepwise entry and re-
moval was set at 0.05 and 0.10, respectively. The signifi-
cance level used was p < 0.05.
Table 3 Expression of markers, gender and their prediction for disease-specific survival in patients with soft tissue
sarcomas (univariate analysis; log-rank test), All = 193, Males = 81, Females = 112
Marker expression Patients (n) Patients (%) Median survival (months) 5-year survival (%) P
Skp2, all
Low 109 56 NR 63 0.050
High 67 45 59 50
Missing 17 9
Skp2, men
Low 50 62 NR 63 0.577
High 23 28 67 61
Missing 8 10
Skp2, women
Low 59 53 NR 63 0.066
High 44 39 49 44
Missing 9 8
ER, all
Low 112 58 123 57 0.725
High 72 67 91 57
Missing 9 5
ER, men
Low 49 60 NR 69 0.089
High 29 36 58 49
Missing 3 4
ER, women
Low 63 56 57 47 0.041
High 43 38 NR 62
Missing 6 5
PGR, all
Low 132 68 NR 62 0.101
High 57 30 52 46
Missing 4 2
PGR, men
Low 64 79 NR 69 0.010
High 15 19 41 33
Missing 2 2
PGR, women
Low 68 61 80 55 0.832
High 42 38 74 51
Missing 2 2
Abbreviations: NR, not reached.
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The National Cancer Data Inspection Board and The
Regional Committee for Research Ethics (REK nord) ap-
proved the study. The material was collected from our ap-
proved biobank for paraffin embedded material and slides.
The Regional Committee approved that written consentfrom the patients for their information to be stored in the
hospital database and used for research was not needed
because most of the material was more than 10 years old,
and most of the patients being dead. The ethics committee
specifically waived the need for consent. Data were ana-
lyzed anonymously.
Figure 2 Survival plots ER and PGR. Disease-specific survival curves for high and low expression of ER and PGR in male (N = 81) and female
(N = 112) patients with soft tissue sarcomas.
Sorbye et al. BMC Clinical Pathology 2013, 13:9 Page 6 of 13
http://www.biomedcentral.com/1472-6890/13/9Results
Clinicopathological variables
Demographic, clinical, and histopathological variables are
shown in Table 1. Patient age ranged from 0–89 years
(mean 55 years), and 42% of patients (81/193) were male.
Treatment for all patients included surgery: 104 patients
received surgery only; 52 patients received surgery and
radiotherapy; 28 patients received surgery and chemother-
apy; 9 patients received surgery, radiotherapy and chemo-
therapy. The 5-year survival for patients with wide and
non-wide resection margins was 66% and 46% respect-
ively, Table 1.
Inter-observer variability
There was good scoring agreement between the two inves-
tigating pathologists. The IHC scores from each observer
were compared using a two-way random effects model
with absolute agreement definition. The intra-class
correlation coefficients (reliability coefficients, r) obtained
from these results were 0.94 for Skp2 (p < 0.001), 0.92 for
ER (p < 0.001) and 0.96 for PGR (p < 0.001).Univariate analyses
Nationality, histology, tumor size, malignancy grade and
surgical margins were all significant indicators for disease-
specific survival (DSS) in univariate analyses (Table 1).
Table 2 shows the percentage of high expression of ER,
PGR and Skp2 in the different histological subtypes. Chi-
square test showed no differences in overall expression of
ER, PGR and Skp2 with respect to the different histological
subtypes.
In univariate analyses, increased expression of Skp2
(p = 0.050) correlated significantly with reduced DSS,
(Table 3 and Figure 2). No such relationship was appar-
ent for ER and PGR when males and females were com-
bined in one group.
In subgroup analyses (Tables 3 and 4), increased PGR
expression in men (p = 0.010) and in patients older than
60 years (p = 0.043) was associated with a reduced DSS.
Increased ER expression in women was associated with
longer DSS (p = 0.041). High expression of ER were asso-
ciated with favorable survival in patients with rhabdomyo-
sarcoma (N = 9, p = 0.040). High expression of ER was
Table 4 Expression of markers, age and their prediction for disease-specific survival in patients with soft tissue
sarcomas (univariate analysis; log-rank test)
Marker expression Patients (n) Patients (%) Median survival (months) 5-Year survival (%) P
Skp2, <60 years, N = 99
Low 52 53 NR 71 0.074
High 38 38 67 56
Missing 9 9
Skp2, ≥60 years, N = 94
Low 57 61 80 57 0.188
High 29 31 36 42
Missing 8 9
ER, <60 years, N = 99
Low 55 56 127 59 0.197
High 40 40 NR 67
Missing 4 4
ER, ≥60 years, N = 94
Low 57 61 80 55 0.293
High 32 34 52 44
Missing 5 5
PGR, <60 years, N = 99
Low 63 64 NR 67 0.488
High 34 34 NR 55
Missing 2 2
PGR, ≥60 years, N = 94
Low 69 73 91 57 0.043
High 23 24 39 32
Missing 2 2
Abbreviations: NR, not reached.
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coma (N = 12, p = 0.010). There were no significant differ-
ences in survival according to high or low expression of
Skp2 in any of the histological subtypes (data not shown).
In patients with low expression of ER (N = 112), men had
better 5-year survival (69%) compared to women (47%, p =
0.002), while there were no differences (p = 0.376) between
men and women in patients with high expression of ER (N
= 72). In patients with low expression of PGR (N = 132),
men had better 5-year survival (69%) compared to women
(55%, p = 0.013), while there were no differences (p = 0.271)
between men and women in patients with high expression
of PGR (N= 57). There were no differences in survival be-
tween men and women in univariate analyses of patients
with low (N = 109, p = 0.529) or high (N = 67, p = 0.233) ex-
pression of Skp2 (data not shown).
In co-expression analyses (Table 5) Skp2 negative / ER
negative profile was associated with longer DSS (p = 0.049).
In women a Skp2 positive and ER negative profile was asso-
ciated with reduced DSS (p = 0.021), Table 5 and Figure 3.
In men a double negative ER/PGR profile was associatedwith longer DSS (p = 0.013) while in women a double posi-
tive ER/PGR was associated with longer DSS (p = 0.001). In
patients younger than 60 years the combination ER nega-
tive and PGR positive was associated with shorter DSS. In
the whole cohort of patients a triple positive expression of
ER, PGR and Skp2 was associated with longer DSS (p =
0.005), Figure 3. Triple negative expression of ER, PGR and
Skp2 was also associated with longer DSS, but not statisti-
cally significant (p = 0.068), Figure 3. ER negative / PGR
positive co-expression was associated with shorter DSS re-
gardless of Skp2 expression, Table 6.
Taking into consideration the possible distortion of
results by gender-related sarcomas (i.e. leiomyosarcoma in
uterus) we have attempted to exclude these sarcomas and
recalculate all analyses. There were no significant differ-
ences in the results compared to those obtained without
exclusion of gender-related sarcomas (data not shown).
Multivariate analyses
Significant demographic, clinicopathological and expression
variables from the univariate analyses were entered into the
Table 5 Co-expression of Skp2/ER, Skp2/PGR and their prediction for disease-specific survival in patients with soft
tissue sarcomas (univariate analysis; log-rank test), All = 193, Men = 81, Women = 112
Co-expression Patients (n) Patients (%) Median survival (months) 5-Year survival (%) P
Skp2 / ER, all
Low/low 66 34 NR 67 0.049
Low/high 39 20 91 59
High/low 35 18 57 44
High/high 30 16 NR 58
Missing 23 12
Skp2 / ER, men
Low/low 33 41 NR 72 0.427
Low/high 16 20 37 50
High/low 11 14 NR 72
High/high 11 14 63 58
Missing 10 12
Skp2 / ER, women
Low/low 33 29 127 61 0.021
Low/high 23 21 91 65
High/low 24 21 31 32
High/high 19 17 NR 58
Missing 13 12
Skp2 / PGR, all
Low/low 80 41 NR 71 0.056
Low/high 25 13 54 46
High/low 40 21 59 49
High/high 27 14 67 51
Missing 21 11
Skp2 / PGR, men
Low/low 41 51 NR 73 0.141
Low/high 7 9 26 29
High/low 18 22 NR 61
High/high 5 6 67 60
Missing 10 12
Skp2 / PGR, women
Low/low 39 35 NR 68 0.234
Low/high 18 16 75 54
High/low 22 20 29 39
High/high 22 20 57 49
Missing 11 10
Abbreviations: NR, not reached.
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variate analyses, age (p = 0.012), malignancy grade (p <
0.001), wide resection margins (p = 0.010), ER negative /
PGR positive co-expression (p = 0.002) and ER positive /
PGR negative co-expression (p = 0.015) were independent
negative prognostic factors for DSS. In women, expressionof Skp2 (p = 0.006) was associated with reduced DSS. In
women, tumor size (p = 0.020) and nationality (p = 0.014)
were independent prognostic factors for DSS, Table 7. In
multivariate analyses co-expression of Skp2/ER or Skp2/
PGR were not stronger prognosticators for DSS than single
expression of Skp2, ER and PGR (data not shown).
Figure 3 Survival plots co-expression. Disease-specific survival curves for co-expression of Skp2, ER or PGR in males (N = 81), females (N = 112)
and co-expression of ER and PGR in Skp2 negative (N = 109) and Skp2 positive (N = 67) patients.
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In this large-scale study, we evaluated the prognostic sig-
nificance of expression of Skp2 related to age, gender,
ER and PGR in 193 STS patients. Our hypothesis was
confirmed. We found diverse prognostic DSS impacts
from gender related expression of Skp2, ER, PGR and
DSS in STS. In men, but not women, an ER positive/PGR negative co-expression profile was an independent
negative prognostic factor for DSS. In women, but not
men, high expression of Skp2 was associated with re-
duced DSS. High expression of ER reduced the negative
impact of Skp2 in women. While women with the Skp2
positive / ER positive phenotype had favorable survival,
women with the Skp2 positive / ER negative phenotype had
Table 6 Co-expression of ER/PGR and their prediction for disease-specific survival in patients with soft tissue sarcomas
(univariate analysis; log-rank test)
Co-expression Patients (n) Patients (%) Median survival (months) 5-year survival (%) P
ER / PGR, all, N = 193
Low/low 84 44 NR 69 <0.001
Low/high 26 13 38 24
High/low 41 21 62 52
High/high 31 16 NR 64
Missing 11 6
ER / PGR, men, N = 81
Low/low 39 48 NR 79 0.013
Low/high 9 11 41 33
High/low 23 28 63 53
High/high 6 7 37 33
Missing 4 5
ER / PGR, women, N = 121
Low/low 45 40 89 59 0.001
Low/high 17 15 31 19
High/low 18 16 29 50
High/high 25 22 NR 72
Missing 7 6
ER / PGR, <60 years, N = 99
Low/low 41 41 NR 72 0.001
Low/high 13 13 31 23
High/low 19 19 NR 58
High/high 21 21 NR 76
Missing 5 5
ER / PGR, ≥60 years, N = 94
Low/low 43 46 NR 64 0.052
Low/high 13 14 39 26
High/low 22 23 58 47
High/high 10 11 37 40
Missing 6 6
ER / PGR, Skp2 low, N = 109
Low/low 55 50 NR 76 0.068
Low/high 9 8 68 25
High/low 23 21 91 61
High/high 16 15 75 56
Missing 6 6
ER / PGR, Skp2 high, N = 67
Low/low 21 31 89 55 0.005
Low/high 14 21 31 29
High/low 17 25 29 42
High/high 13 19 NR 77
Missing 2 3
Abbreviations: NR, not reached.
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Table 7 Results of Cox regression analysis summarizing prognostic factors in patients with soft tissue sarcomas
All patients, N = 193 Men, N = 81 Women, N = 112
Factor Hazard ratio 95% CI P Hazard ratio 95% CI P Hazard ratio 95% CI P
Age
0–59 years 1.00 1.00 1.00
≥60 years 1.84 1.15-2.95 0.012 1.69 0.65-4.41 0.282 1.51 0.83-2.77 0.179
Nationality
Norwegian 1.00 1.00 1.00
Russian 1.49 0.88-2.52 0.143 1.39 0.41-4.66 0.598 2.51 1.20-5.21 0.014
Tumor size
<5 cm 1.00 0.138* 1.00 0.668* 1.00 0.020*
5–9 cm 1.47 0.79-2.73 0.226 1.68 0.54-5.25 0.372 1.71 0.77-3.77 0.187
≥10 cm 1.91 1.01-3.60 0.047 1.32 0.40-4.39 0.652 3.14 1.38-7.15 0.006
Malignancy grade FNCLCC
1 1.00 <0.001* 1.00 <0.001 1.00 0.004*
2 2.72 1.36-5.46 0.005 3.07 0.86-10.96 0.084 4.33 1.76-10.67 0.001
3 4.61 2.26-9.40 <0.001 15.47 4.36-54.97 <0.001 4.23 1.64-10.89 0.003
Resection margins
Wide 1.00 1.00 1.00
Non-wide 1.87 1.16-3.02 0.010 7.69 2.67-22.16 <0.001 0.81 0.42-1.54 0.512
Skp2
Low 1.00 1.00 1.00
High 1.48 0.87-2.52 0.151 0.46 0.19-1.12 0.088 2.52 1.31-4.85 0.006
ER / PGR
Low/low 1.00 0.006* 1.00 0.004* 1.00 0.216*
Low/high 2.64 1.43-4.85 0.002 4.99 1.31-18.97 0.018 1.91 0.89-4.11 0.097
High/low 2.07 1.15-3.73 0.015 8.35 2.55-27.36 <0.001 1.76 0.79-3.93 0.170
High/high 1.16 0.57-2.38 0.682 4.50 0.96-21.13 0.056 0.92 0.36-2.35 0.868
* Overall significance as a prognostic factor. The difference between the individual p-value and total p-value in the multivariate analysis is relevant in cases where
there are more than two categories for a given variable. Overall p-value is calculated based on a general assessment of all categories for the given variable, but
the individual p-value only calculates the significance of a given category versus the reference category.
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prognostic evaluation of Skp2 related to the female hor-
mone receptors ER and PGR in STS.
Expression of ER and PGR is a routinely investigated indi-
cator of endocrine therapy success in breast cancer [12,13]
and a modest, but significantly better overall survival of anti-
estrogen receptor therapy has been documented [14]. ER and
PGR are also reported to be positive prognosticators of uter-
ine leiomyosarcomas [15]. However, extra-uterine sarcomas
have barely been explored in this context. The distribution
and prognostic value of expression of these steroid
hormone receptors in STS are therefore of great scien-
tific interest. In our study, in the univariate analyses,
ER showed a significantly favorable influence on sur-
vival in female patients, but not in males. PGR was an
unfavorable prognosticator for men, but not for
women. In multivariate analysis ER positive / PGRnegative co-expression is an independent negative
prognostic factor for DSS in males, but not in females.
We have modified the Allred score for STS and used 1%
positivity as cut-off value [7,16]. The strong and moderate
(score 3 and 2, respectively) hormone receptor expression
occurred mostly in sarcomas of uterus, pelvis and breast,
while the weak (score 1) expression of both ER and PGR
was surprisingly evenly distributed among location, gender
and age. Generally, 39% of the tumors expressed ER and
30% expressed PGR in our material. Roughly half of the pa-
tients expressed at least one of these receptors. The findings
are in partial agreement with findings of Chaudhuri et al.
[17] who found ER to be positive in 24% of STS.
Huang et al. suggested that the therapeutic strategies
designed to reduce Skp2 may play an important clinical
role in treatment of breast cancer cells, especially ER/
HER2 negative breast cancers [18]. Voduc et al. found
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specific survival in univariate analyses. Double positive
expression of cyclin E / Skp2 was associated with young
age at diagnosis, grade 3 tumors, ER-negative status and
HER2 negative status [19]. Zheng et al. found that
higher levels of Skp2 were detected more frequently in
ER-negative breast cancer tumors and tumors meta-
static to the axillary lymph nodes [20]. Signoretti et al.
also found that higher levels of Skp2 are present more
frequently in ER-negative tumors than in ER-positive
cases. The subset of Skp2 positive / ER negative breast
carcinomas were also characterized by high tumor grade
and HER2 negative [21]. In our material, the five year
DSS in Skp2 positive / ER negative women with STS
was 32% compared to 58% in Skp2 positive / ER positive
women (P = 0.021).
In our previous work we have shown that ER and
PGR expression possess variable prognostic signifi-
cance depending on gender, both per se and in co-
expression with TGF-β, fascin and Akt isoforms [7-9].
In the present study, the prognostic diversity of Skp2,
ER and PGR in men and women was seen in the differ-
ent co-expression profiles: female patients with Skp2
positive / ER negative profile had decreased survival
rates. For men, the Skp2 negative / ER negative profile
was the most favorable phenotype. PGR expression in
men, but not women, was associated with a shorter
DSS. ER expression in women, but not men, was asso-
ciated with a longer DSS. The ER negative / PGR posi-
tive profile was a significantly unfavorable factor for
the whole patient cohort both in univariate and multi-
variate analysis. Interestingly, such a profile occurred
in only 2% of patients in one large-scale study based on
3000 breast cancer cases [22], while in our STS study
this profile was seen in 13% of tumors.
The data collection introduced problems in identify-
ing adequate numbers of similar patients with similar
tumors and with the same treatment traditions. These
are well known problems when conducting STS studies.
Our findings are in large hypothesis generating, and to
be more conclusive future STS studies must be based
on large, multi-institutional and multinational studies
with possibilities to establish adequately sized STS patient
cohorts of homogenous tumor groups. However, all tu-
mors investigated herein had mesenchymal derivation and
belong to the same generic group.
Conclusions
In conclusion, there were different prognostic impacts of
expression of Skp2, ER, PGR and DSS in male and female
patients with STS. In men, but not in women, ER positive /
PGR negative co-expression was an independent negative
prognostic factor for DSS. In women, but not in men, ex-
pression of Skp2 was associated with reduced DSS.Competing interests
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